Cir-Predict demonstrated its ability to predict recurrence not only in the data used to develop the model but also in ER+/HER2− breast cancer patients, supporting the prior reports that ctDNA presence is a poor prognostic factor. This evidence concerns the gene ESR1 and breast carcinoma.